Detroit 562 Xenograft Model Service for Head and Neck Cancer

The Detroit 562 cell line, established from a metastatic pharyngeal carcinoma, provides a highly clinically relevant in vivo platform for studying the advanced progression of head and neck malignancies and assessing the potency of novel targeted therapies. As a specialized oncology contract research organization, Alfa Cytology offers a highly robust, turnkey Detroit 562 Xenograft Model Service tailored to help researchers validate their pharmaceutical pipelines with absolute precision and reproducibility.

Overview of Detroit 562 Xenograft Model for Head and Neck Cancer

The Detroit 562 xenograft model serves as a vital pre-clinical translation platform for evaluating head and neck squamous cell carcinomas (HNSCC), with a specific emphasis on metastatic pharyngeal cancers. By transplanting human Detroit 562 carcinoma cells into immunodeficient mice, this model effectively mimics the architectural complexity, cell-to-cell microenvironmental interactions, and specific aggressive tumor signaling pathways observed in advanced clinical settings.

Biologically, the Detroit 562 model presents stable, predictable, and robust growth kinetics that are essential for long-term therapeutic dosing windows. This model retains key molecular characteristics of the original human tumor, including specific mutations in the PIK3CA and TP53 genes, which are prevalent drivers in human pharyngeal cancers. Because it maintains these native molecular targets and displays distinct epithelial properties, the model is extensively utilized worldwide to test the efficacy of small-molecule inhibitors, immunotherapies, antibody-drug conjugates (ADCs), and combination chemoradiation therapies aimed at combating treatment-resistant head and neck tumors.

Fig 1. Overexpression of suppressor of cytokine signaling (SOCS) 1 inhibited the growth of HNSCC cell lines. (Kajiyama T, et al., 2022)

Cell Line Information: Detroit 562

The Detroit 562 cell line was isolated from the pleural fluid of a Caucasian female patient suffering from a primary carcinoma of the pharynx, representing a metastatic site. These cells display an adherent, epithelial morphology under standard in vitro culture parameters and possess well-characterized genomic alterations that align with aggressive clinical HNSCC phenotypes.

Partnering with Alfa Cytology guarantees that your pre-clinical HNSCC studies are backed by exceptional scientific design, meticulous tracking, and verified data reproducibility. Our professional scientific team carefully oversees every stage of the modeling process---from strict baseline cell quality checks to high-resolution data delivery---empowering biotechnology and pharmaceutical innovators to seamlessly accelerate their therapeutic molecules toward clinical evaluation.

Our Services

Workflow of Detroit 562 Xenograft Model Construction

• Cell Culture & Quality Control: Human Detroit 562 cells are expanded in vitro in certified growth media under optimized, strictly monitored environmental parameters. Comprehensive quality control validation, including mandatory STR profiling and mycoplasma clearance testing, is performed prior to inoculation to ensure total phenotypic identity and biological purity.
• Host Selection & Acclimatization: Healthy, standardized immunocompromised mice (such as BALB/c Nude or NOD/SCID strains) are carefully selected based on the specific requirements of the experimental design. The animals are housed within controlled facility parameters for a set duration to guarantee physiological baseline stability and optimal welfare.
• Precision Inoculation: A calibrated suspension of high-viability Detroit 562 cells is prepared and blended with a validated biological matrix carrier to improve spatial distribution and support initial survival. The mixture is precisely injected in vivo into the designated cohorts via subcutaneous or orthotopic pharyngeal routes.
• Longitudinal Growth Tracking: Following successful tumor engraftment, tumor growth kinetics are tracked systematically using high-precision digital calipers under continuous health monitoring. Animal body weights, physiological baselines, and general behavior are routinely logged to compile an accurate growth curve.
• Stratification & Dosing: Once the expanding tumors reach a predetermined, statistically optimal volume range, the animals are randomized into specific therapeutic cohorts. This stratification balances baseline parameters perfectly across all groups before customized dosing protocols begin.

Fig 2. Detroit 562 Xenograft Model Construction Workflow

Case Study - Detroit 562 Xenograft Model Development

In a recent pre-clinical validation study, a Detroit 562 xenograft model was successfully constructed to evaluate a novel small-molecule inhibitor targeting the PI3K signaling pathway. Following precision subcutaneous inoculation into BALB/c Nude mice, the Detroit 562 tumors achieved a uniform engraftment rate exceeding 90% and exhibited steady, aggressive growth kinetics over a 30-day monitoring timeline. Tumor-bearing animals randomized into the treatment cohort demonstrated a statistically significant, dose-dependent reduction in tumor volume compared to the control group, validating the model's excellent predictive reliability and high sensitivity for screening targeted pharyngeal cancer therapies.

Why Choose Alfa Cytology?

• Oncology Domain Expertise: Deep specialization in establishing and maintaining advanced squamous cell carcinoma models, providing reliable in vivo platforms for complex head and neck cancer studies.
• Rigorous Quality Control: Stringent validation at every phase of in vitro and in vivo processing to completely eliminate confounding biological variables.
• Tailored Experimental Design: Flexible study frameworks accommodating custom mouse strain choices, specific dosing routes, and orthotopic or subcutaneous inoculation pathways.
• High-Resolution Deliverables: Every project concludes with a detailed, audit-ready data report containing high-precision digital caliper metrics and robust statistical validations.

Contact us

Accelerating your head and neck oncology pipeline requires a pre-clinical partner with the technical proficiency to execute rigorous in vivo studies flawlessly. If you are looking to advance your therapeutics for advanced pharyngeal carcinoma or require custom pre-clinical validation using our Detroit 562 platform, please reach out to us today. The dedicated scientific team at Alfa Cytology is fully prepared to assist you with experimental design, provide operational insights, and deliver the high-quality data your pipeline needs to succeed; please feel free to contact us to get started.

For research use only. Not intended for any clinical use.